AstraZeneca acquires bacterial vaccine biotech, Omniose
After two years of fruitful collaboration, AstraZeneca is opting to acquire its partner and bacterial vaccine technology startup, Omniose. For an …
Post
-
-
Australia’s largest early-phase clinical trial network expands to Sydney
There is no denying that Australia hits above its weight class in early clinical research. With approvals depending solely on local Human …
-
Longevity sector ambitions outpace regulatory and investment frameworks
The longevity market is gaining significant traction, with capital investment and deal count at a record high for 2025 and …
-
Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
Following a series of industry-defining readouts for its personalised cancer vaccine intismeran autogene, Moderna is eyeing a future bigger than …
-
ProBio signs global antibody licensing deal with AbTis
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an …
-
Democrat midterm landslide spells greater Trump oversight, marginal reforms
On 4 November, the Democrats made history by winning the Senate and the House in the US midterm elections – …
-
Lilly-backed Oyster Therapeutics raises $60m for neurological degraders
Oyster Therapeutics, formerly known as Kesmalea Therapeutics, has closed a $60m Series A-2 financing round to advance targeted protein degraders …
-
VC funding in Europe falls short at early-stage investment hurdles
While Europe is often lauded for its robust science, late-stage investment has historically been challenging to secure. Yet speakers at …
-
Pentagon drops WuXi AppTec from Chinese military company list
The US Department of Defence (DoD) has removed WuXi AppTec from its list of designated Chinese military companies, easing geopolitical …
-
How Kenya has become a clinical logistics hub for sub-Saharan Africa
Sub-Saharan Africa holds significant potential for clinical trials, with Kenya growing in status as a key logistics location to unlock …
-
China’s burgeoning novel medicines success presents opportunity for Europe
In recent years, China has positioned itself as a key hub for innovative medicines development, with the country having flourished …
-
Delix Therapeutics raises $100m for zalsupindole development
Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of zalsupindole (DLX001), an …
-
Charles River agrees $470m deal for Frontage assets
Charles River Laboratories International (CRL) has signed definitive agreements to acquire Frontage Holdings’ bioanalysis and drug metabolism and pharmacokinetics (DMPK) …
-
Network Bio partners with Duke University on AI disease models
US-based Network Bio has entered into a research collaboration with Duke University to develop artificial intelligence (AI) models of human …
-
Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug
China's National Medical Products Administration (NMPA) has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid …
